Allogene Therapeutics
ALLOAllogene Therapeutics is a clinical-stage biotechnology company pioneering the development of genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases.
Earnings
Next report
Nov 5, 2026 (in 2 months)Valuation & ratios
Segments
By segment
Competitors
By market cap
By net margin
Profile
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases. Unlike autologous treatments, the company's off-the-shelf product candidates are derived from healthy donors, aiming to provide faster, more scalable, and more reliable cell therapies. The company leverages advanced gene-editing technologies and proprietary manufacturing to create a pipeline of potentially curative treatments for aggressive malignancies and chronic autoimmune conditions.
A pioneer in allogeneic CAR T therapy led by former Kite Pharma executives, focusing on transitioning cell therapy from specialized centers to broader community settings.
FAQ
- What is Allogene Therapeutics's market cap?
- Allogene Therapeutics (ALLO) has a market capitalization of $704.8M and trades on NASDAQ.
- What is Allogene Therapeutics's revenue and profitability?
- Allogene Therapeutics generated $4.6M in trailing twelve-month revenue with a net loss of $165.5M, representing a net margin of -1170863.6%, with free cash flow of -$102.6M. These figures are based on the Q2 2026 filing.
- Who are Allogene Therapeutics's competitors?
- Allogene Therapeutics's key competitors include CRISPR Therapeutics, Gilead Sciences, Inc., Bristol-Myers Squibb, and others. These companies compete in similar markets and product categories.
- Who does Allogene Therapeutics partner with?
- Allogene Therapeutics's notable partners include Les Laboratoires Servier SAS, Cellectis, S.A., Arbor Biotechnologies, and others.
- Where is Allogene Therapeutics headquartered?
- Allogene Therapeutics is headquartered in United States of America and employs approximately 361 people. It has been publicly traded since 2018.
